The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Clinical Factors Associated With Treatment Resistance in Major Depressive Disorder: Results From a European Multicenter Study
Open accessAbstract
OBJECTIVES: Very few studies have investigated clinical features associated with treatment-resistant depression (TRD) defined as failure of at least 2 consecutive antidepressant trials. The primary objective of this multicenter study was to identify specific clinical and demographic factors associated with TRD in a large sample of patients with major depressive episodes that failed to reach response or remission after at least 2 consecutive adequate antidepressant treatments. METHOD: A total of 702 patients with DSM-IV major depressive disorder, recruited from January 2000 to February 2004, were included in the analysis. Among them, 346 patients were considered as nonresistant. The remaining 356 patients were considered as resistant, with a 17-item Hamilton Rating Scale for Depression score remaining greater than or equal to 17 after 2 consecutive adequate antidepressant trials. Cox regression models were used to examine the association between individual clinical variables and TRD. RESULTS: Among the clinical features investigated, 11 variables were found to be associated with TRD. We found anxiety comorbidity (p < .001, odds ratio [OR] = 2.6), comorbid panic disorder (p < .001, OR = 3.2) and social phobia (p = .008, OR = 2.1), personality disorder (p = .049, OR = 1.7), suicidal risk (p = .001, OR = 2.2), severity (p = .001, OR = 1.7), melancholia (p = .018, OR = 1.5), a number of hospitalizations > 1 (p = .003, OR = 1.6), recurrent episodes (p = .009, OR = 1.5), early age at onset (p = .009, OR = 2.0), and nonresponse to the first antidepressant received lifetime (p = .019, OR = 1.6) to be the factors associated with TRD. CONCLUSIONS: Our findings provide a set of 11 relevant clinical variables associated with treatment resistance in major depressive disorder that can be explored at the clinical level. The statistical model used in this analysis allowed for a hierarchy of these variables (based on the OR) showing that comorbid anxiety disorder is the most powerful clinical factor associated with TRD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This comorbidity pattern may also affect treatment outcomes, with pharmacotherapy studies indicating that comorbid SAD is associated with a poorer course of illness (Mulder, Joyce, Frampton, Luty, & Sullivan, 2006), treatment-resistant depression (Souery et al., 2007), and a greater number and earlier onset of depressive recurrences compared with patients without comorbid SAD (Holma, Holma, Melart”
From An Integrated, Acceptance-Based Behavioral Approach for Depression With Social Anxiety: Preliminary Results (2014) · cites this paper as Souery et al., 2007
In the citing paper
“Prevalence estimates of TRS, TRD, and treatment resistant OCD vary from 20-60% of the population with the condition. 26, 35–40”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [39]
In the citing paper
“Timing may add heterogeneous features: certain individuals may change readily with respect to certain symptoms, whereas other subjects may have opposite tendencies [41].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [41]
In the citing paper
“The basic flaw is to assume improvement to be a unitary phenomenon [41].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [41]
In the citing paper
“Comorbidities such as substance use disorder can undermine previously effective maintenance therapy [18]”
In the citing paper
“Approximately only one in two patients with major depressive disorder (MDD) respond to their antidepressant treatment ( Rush et al., 2006 , Souery et al., 2007 , Thomas et al., 2013 )”
From Self-blame-selective hyper-connectivity between anterior temporal and subgenual cortices predicts prognosis in major depressive disorder (2023) · cites this paper as Souery et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Lecrubier, Y., Sheehan, D., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., Janavs, J., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83296-8 · Cited by 3,513
Self-citationSheehan, D., Lecrubier, Y., Harnett Sheehan, K., Janavs, J., Weiller, E., Keskiner, A., Schinka, J., Knapp, E., Sheehan, M., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83297-x · Cited by 2,149
Self-citationOstwald, P. F. (1960) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1960.14.4.817 · Cited by 1,422
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
(1997) · PubMed · Cited by 727
Perlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689
Treatment resistant depression: methodological overview and operational criteria
Souery, D., Amsterdam, J. D., de Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O., Racagni, G., Zohar, J., & Mendlewicz, J. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00004-2 · Cited by 443
Self-citation
Research works printed but not linked: 1
- a Copyright Daniel Souery, M.D. early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2004;55:875-881
Cited by
Sorted by citations
Items 401–500 of 526
Clinical and epidemiological predictors of treatment-resistant depression
Cusin, C., & Meyer, A. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00002-5 · Cited by 2
Comorbidités psychiatriques et résistance thérapeutique
Molière, F. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2014.09.052 · Cited by 2
Fleck, M. P., Berlim, M. T., Lafer, B., Sougey, É. B., Porto, J. A. D., Brasil, M. A. A., Juruena, M. F., & Hetem, L. A. (2009) · Cited by 2
Characterising the severity of treatment resistance in unipolar and bipolar depression
Taylor, R., Strawbridge, R., Young, A. H., Zahn, R., & Cleare, A. J. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1004 · Cited by 2
Peng, H., Jia, J., Lu, Y., & Zheng, H. (2022) · Biomedicines · doi:10.3390/biomedicines10112759 · Cited by 2
Contribution of serotonin 5-HT2A receptor to antidepressant effect of serotonergic psychedelics
Ibi, D. (2023) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22141 · Cited by 2
Fennema, D., Barker, G. J., O’Daly, O., Duan, S., Godlewska, B. R., Goldsmith, K., Young, A. H., Moll, J., & Zahn, R. (2024) · Psychological Medicine · doi:10.1017/s0033291724001144 · Cited by 2
Dalrymple, K. L., Wahrer, K. S., Walsh, E., Rosenstein, L., & Zimmerman, M. (2023) · Journal of Cognitive Psychotherapy · doi:10.1891/jcp-2022-0014 · Cited by 1
Kautzky, A., Dold, M., Bartova, L., Spies, M., Kranz, G. S., Souery, D., Montgomery, S., MENDLEWICZ, J., Zohar, J., Fabbri, C., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.1038 · Cited by 1
Self-citationChapter 9. Translational Neurobiological Approaches to Precision Medicine for Fear and PTSD
Harnett, N. G., Seligowski, A. V., Pine, D. S., & Ressler, K. J. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg09 · Cited by 1
Treatment resistant depression: A case of Muenke syndrome
Faugère, M., Cermolacce, M., Richieri, R. M., & Lançon, C. (2025) · L Encéphale · doi:10.1016/j.encep.2024.10.006 · Cited by 1
Hwang, S. H., Kim, M., & Ham, B. (2025) · Psychiatry Investigation · doi:10.30773/pi.2024.0203 · Cited by 1
Hopwood, M., Codyre, D., Barton, D., Scott, E. M., Puig, A., King, J., & Hickie, I. B. (2025) · Research Directions Depression · doi:10.1017/dep.2025.10001 · Cited by 1
TMS is needed in Public Mental Health Services
PRIDMORE, S. A., Fitzgerald, P. B., & Peterson, G. M. (2025) · Australasian Psychiatry · doi:10.1177/10398562251393795 · Cited by 1
Moser, M., Barrett, A., Woll-Weber, C. F. J., Fonagy, P., Luyten, P., & Campbell, C. (2026) · Depression and Anxiety · doi:10.1155/da/6172409 · Cited by 1
The Role of Psychotherapy in the Management of Treatment‐resistant Depression
Thase, M. E. (2013) · Wiley eBooks · doi:10.1002/9781118556719.ch8 · Cited by 1
Shirayama, Y., Takahashi, M., Suzuki, M., Kimura, A., & Sato, K. (2013) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2013.31a015 · Cited by 1
Pharmacogenomic testing for treatment resistant depression
Leckband, S. G. (2014) · Mental Health Clinician · doi:10.9740/mhc.n207183 · Cited by 1
Dépression résistante : vers une prise en considération des comorbidités et de la iatrogénie
Haesebaert, F. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2014.09.051 · Cited by 1
松永, 美., 鈴木, 伸., 岡本, 泰., Yoshimura, S., 国里, 愛., 神人, 蘭., 吉野, 敦., 西山, 佳., & 山脇, 成. (2012) · 行動療法研究 · doi:10.24468/jjbt.38.3_181 · Cited by 1
Depressione resistente al trattamento: stato dell’arte. Parte I. Nosografia e clinica
Luchini, F., Cosentino, L., Pensabene, L., Mauri, M., & Lattanzi, L. (2014) · Rivista di psichiatria · doi:10.1708/1668.18260 · Cited by 1
Models for Evaluating Therapeutic Resistance of Depression
Mazo, G. E., Незнанов, Н. Г., & Krizhanovskii, A. S. (2016) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-016-0280-3 · Cited by 1
Does the family “need” depression? A pilot study of family consultations
Janusz, B., Chwal-Błasińska, M., Michałowska, K., Furgał, M., Bobrzyński, J., de Barbaro, B., Siwek, M., & Dudek, D. (2015) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/39750 · Cited by 1
Neural markers of depression in MRI
Lai, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00037-2 · Cited by 1
Magnetic Resonance Imaging as a Translational Research Tool for Major Depression
Lai, C. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_12 · Cited by 1
Binder, M. R. (2022) · American Journal of Clinical and Experimental Medicine · doi:10.11648/j.ajcem.20221001.15 · Cited by 1
Clinical associations with treatment resistance in depression: An electronic health record study
Coombes, B. J., Sánchez-Ruiz, J. A., Fennessy, B., Pazdernik, V. K., Adekkanattu, P. M., Núñez, N. A., Lepow, L., Beaupre, L. M., Ryu, E., Talati, A., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116203 · Cited by 1
Chapter 2. The Future Of Precision Transcranial Magnetic Stimulation In Psychiatry
Philip, N. S., Zandvakili, A., & Berlow, Y. A. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg02 · Cited by 1
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1
Exploring the Efficacy of Distance Treatment for Anxiety and Anxiety Sensitivity
Olthuis, J. V. (2013) · DalSpace (Dalhousie University) · Cited by 1
THE EFFECT OF A MOTIVATIONAL INTERVIEWING STYLE IN COGNITIVE THERAPY FOR DEPRESSION
Carlin, E. (2010) · UA Campus Repository (The University of Arizona) · Cited by 1
Bosaipo, N. B. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2016.tde-26082016-153726 · Cited by 1
Havinga, P. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.112725525 · Cited by 1
Phenotype-by-phenome-wide association study of treatment resistant depressionPreprint
Coombes, B. J., Sánchez-Ruiz, J. A., Fennessy, B., Pazdernik, V., Adekkanattu, P. M., Núñez, N. A., Lepow, L., Ryu, E., Talati, A., Jenkins, G. D., et al. (2022) · medRxiv · doi:10.1101/2022.08.23.22279074 · Cited by 1
The Nature and Treatment of Therapy-Resistant Depression
Kennedy, S. H., Rizvi, S. J., & Giacobbe, P. (2010) · Modern trends in psychiatry · doi:10.1159/000319516
Darstellung pathophysiologisch und therapeutisch relevanter Hirnareale psychiatrischer Erkrankungen
Shababi-Klein, J. (2013) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-14298
Kautzky, A., Calati, R., Baldinger, P., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Serretti, A., Lanzenberger, R. R., & Kasper, S. (2014) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(14)70636-4
Self-citationThe AMSP-project: Pharmacovigilance in psychiatry - Presentation, challenges and results
Baumann, P. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2014.09.050
Muhonen, L. H. (2008) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)
Revista Brasileira de Psiquiatria
Lepine, B. A., Moreno, R. A., Campos, R. N., & Couttolenc, B. F. (2012)
Neurotoxicity of major depressive disorder: a neuroimaging and neuropsychological study.
Serra-Blasco, M. (2015) · TDX (Tesis Doctorals en Xarxa)
Robinson, D., & Portland, K. B. (2012)
Familial clustering of suicide and major depressive disorder: an observational analysis
Walano, N. (2016) · D-Scholarship@Pitt (University of Pittsburgh)
Willner, P., Borsini, F., & McArthur, R. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00038-2
Monoamine Oxidase A in Relation to Subtypes and Treatment of Major Depressive Disorder
Chiuccariello, L. (2015) · TSpace (University of Toronto)
Clinical predictors of antidepressant response and remission in treatment resistant depression
Calati, R., Souery, D., Massat, I., Kasper, S. F., Montgomery, S., Zohar, J., Mendlewicz, J., & Serretti, A. (2007)
Self-citationYang, D. D. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Bazazeh, D. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0375879
なかなか治らないうつに対し，どの様に捉え，どの様に対処すべきだろうか
衡一郎, 渡. (2018) · 杏林医学会雑誌 · doi:10.11434/kyorinmed.49.83
A genome-wide association study of treatment-resistant depression and meta-analysis with STAR*D
Fabbri, C., Kasper, S. F., Kautzky, A., Zohar, J., Souery, D., Montgomery, S. A., Albani, D., Raimondi, I., Dikeos, D., Rujescu, D., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.559
Self-citationKim, K., Yoo, I., Woo, J., Lee, S., D, M. F. M., Mischoulon, D., Papakostas, G. I., Kim, E.-J., Chung, S. H., Ha, J. H., et al. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw043.089
Godin, O., Bennabi, D., Mallet, J., & Haffen, É. (2018) · French Journal of Psychiatry · doi:10.1016/s2590-2415(19)30020-0
Ichiki, M., Masuya, J., & Inoue, T. (2020) · Clinical Neuropsychopharmacology and Therapeutics · doi:10.5234/cnpt.11.54
Chiddaycha, M., & Lueboonthavatchai, P. (2020) · doi:10.21203/rs.3.rs-15831/v1
Elektrokonvulsionstherapie – eine Blackbox?
Falkai, P., & Schmitt, A. (2021) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1253-9343
Mandal, T., Bairy, L. K., Sharma, P. S. V. N., & Valaparla, V. L. (2021) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-021-00302-7
Peripheral biomarkers in Repeated Ketamine Infusions Trial
Geel, A. V. (2021) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2021-14775
Fabbri, C., Kasper, S. F., Kautzky, A., Zohar, J., Souery, D., Montgomery, S., Albani, D., Dikeos, D. G., Rujescu, D., Mendlewicz, J., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.09.119
Self-citationAnxiety disorders in primary care
Dold, M., & Kasper, S. F. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198746638.003.0007
Self-citationMcArthur, R. A., & Borsini, F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00033-3
Taipale, H., Reutfors, J., Tanskanen, A., Tiihonen, J., Mittendorfer‐Rutz, E., DiBernardo, A., Brandt, L., & Brenner, P. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.09.105
Linking major depressive disorder pathogenesis with kynurenine pathway - a literature review
SZAWICA, D., Kuźniar, A., Fularska, K., Oleszko, M., & WĄSIEWICZ, E. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.15.01.003
Dépression résistante aux traitements
Vlaicu, M. B. ̆., & Vlaicu, A. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77862-9.00005-0
Combined Psychotherapy and Somatic Treatments
Teo, D. C. L., Silvio, J. R., Condemarín, R., Nair, S. S., Alfonso, C. A., & Tasman, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_95-1
MDMA-Assisted Therapy for Treatment of PTSD and Beyond
(2023) · Frontiers research topics · doi:10.3389/978-2-8325-3023-8
Lupo, C., Bonetto, G. G., Corral, R. M., Vilapriño, M., Alessandria, H., KANEVSKY, G. A., & Perocco, S. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i161.484
Koshikawa, Y., Onohara, A., Wakeno, M., Takekita, Y., Kinoshita, T., & Kato, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20917
Incidence of treatment-resistant depression during the first mood depressive episode.
Said, M., Hosni, R., Jemli, H., Zgueb, Y., Ouali, U., Zalila, H., Nacef, F., & Jomli, R. (2023) · PubMed Central
Progress in Biomarkers to Improve Treatment Outcomes in Major Depressive Disorder
Vaccarino, S. R., Ceniti, A. K., Rotzinger, S., & Kennedy, S. H. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.024
Mood Disorders in the Twenty-First Century
Young, A. H., Sanches, M., Soares, J. C., & Juruena, M. F. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.002
Badamasi, I. M., Lye, M. S., Ibrahim, N., Razaq, N. A. A., Ling, K., & Stanslas, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4441400/v1
Combined Psychotherapy and Somatic Treatments
Teo, D. C. L., Silvio, J. R., Condemarín, R., Nair, S. S., Alfonso, C. A., & Tasman, A. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_95
Chapter 10. Latent Variable–Based Predictive And Explanatory Disease Models
Paulus, M. P. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg10
(2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.bm01
Da, C. M., Ribeiro, F., Felger, J. C., Treadway, M. T., Goldsmith, D. R., Haroon, E., & Miller, A. H. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg06
(2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.fm01
Chapter 7. Pharmacogenetic Testing: A Tool for Precision Prescribing in Psychiatry
Bousman, C., Forbes, M., & Dunlop, B. W. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg07
Chapter 8. Treatment Prediction Biomarkers For Major Depressive Disorder
Sacchet, M. D., Webb, C. A., & Pizzagalli, D. A. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg08
Chapter 3. Neural Mechanisms Of Bipolar Disorder: Toward Personalized Markers of Future Illness Risk
Phillips, M. L. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg03
Chapter 11. Computational Cognitive Methods For Precision Psychiatry
Huys, Q. J. M. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg11
Vinogradov, S., Mishra, J., Nahum, M., & Ramsay, I. S. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg04
(2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.index
Chapter 13. Moving From Precision to Personalized Psychiatry: Clinical Perspectives on the New Era
Perna, G., & Nemeroff, C. B. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg13
Chapter 1. A Neural Circuit–Informed Taxonomy For Precision Psychiatry
Hack, L. M., Ball, T. M., & Williams, L. M. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg01
Ross, D. A., Cooper, J. J., Arbuckle, M. R., Walker, A. E., & Travis, M. J. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379118.lg14
Hovmand, O. R., Reinholt, N., Christensen, A. B., Bjørnholm, K., Dilling-Hansen, D., & Arnfred, S. (2025) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2025.2507737
Les troubles psychiatriques résistants
Garçon, S. (2015) · Presses universitaires de Grenoble eBooks · doi:10.3917/pug.bouv.2015.01.0113
Adjunctive strategies for treatment-resistant depression
Thase, M. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00011-6
Reply to Jianjie Ju and Hui Chen
Serretti, A. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.09.003
Self-citationLin, S.-C., Fang, C., Hsu, C., Chung, A.-N., Chen, T., Hsu, K.-H., Yeh, C.-C., Zheng, J., Liu, C.-Y., Wu, C., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02269-y
Efecto del Omega-3 (DHA y EPA) en adultos jóvenes con depresión bajo medicación psiquiátrica
Vite, J. E. B., Sosa, M. C. S., & Ariza‐Ortega, J. A. (2025) · South Florida Journal of Development · doi:10.46932/sfjdv6n11-002
Spijker, J. (2021) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2586-3_8
Taipale, H. T., Reutfors, J., Tanskanen, A., Brandt, L., Tiihonen, J., DiBernardo, A., Mittendorfer-Rutz, E., & Brenner, P. (2020) · Figshare · doi:10.6084/m9.figshare.12299210
Denee, T., Kerr, C., Richards, S., Dennis, N., Foix-Colonier, A., Fischer, C., & Larkin, F. (2024) · Figshare · doi:10.6084/m9.figshare.26825477
Phillips, A. (2019) · ResearchWorks at the University of Washington (University of Washington)
Paillé, M. T. (2019) · Mspace (University of Manitoba)
Metadata
- Authors
- Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., Zohar, J., Mendlewicz, J., & Group for the Study of Resistant Depression (GSRD)
- Affiliations
- Université Libre de Bruxelles (BE)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-07-15
- Volume
- 68
- Issue
- 07
- Pages
- 1062-1070
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1969010498
- Cited by
- 521
- References
- 22
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 26 · 2023: 30 · 2022: 26 · 2021: 54 · 2020: 35 · 2019: 46 · 2018: 31 · 2017: 22 · 2016: 23 · 2015: 25 · 2014: 27 · 2013: 29 · 2012: 21
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Les Laboratories Pierre Fabre
- Fonds De La Recherche Scientifique - FNRS
- Servier
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- treatment-resistant depression, major depressive disorder, antidepressant non-response, anxiety comorbidity, panic disorder, social anxiety disorder, personality disorders, suicide risk, melancholia, depression severity, hospitalization, recurrent depression, age of onset, risk factors
- MeSH terms
- Adult, Aged, Antidepressive Agents, Mental Disorders, Major Depressive Disorder, Drug Resistance, Europe, Female, Follow-Up Studies, Hospitalization, Humans, Male, Middle Aged, Recurrence, Comorbidity, Treatment Failure, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
